Reference(s)
Click here to return to the Reference Table

Cancer type: MFH/Fibrosarcoma


HGF/SF expression

Reference Number: 141
Fukuda, T. et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 48, 757-62 (1998).
PubMed link      E-mail link

Met expression

Reference Number: 141
Fukuda, T. et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 48, 757-62 (1998).
PubMed link      E-mail link

Reference Number: 144
Oda, Y., Naka, T., Takeshita, M., Iwamoto, Y. & Tsuneyoshi, M. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol 31, 709-16 (2000).
PubMed link      E-mail link

Reference Number: 664
Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi X, Hoang BH. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res. 68, 3350-60 (2008)
PubMed link      E-mail link

Reference Number: 693
Schirosi L, Lantuejoul S, Cavazza A, Murer B, Yves Brichon P, Migaldi M, Sartori G, Sgambato A, Rossi G. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Am J Surg Pathol. 32, 1627-42 (2008)
PubMed link      E-mail link

Reference Number: 856
Liang H, O'Reilly S, Liu Y, Abounader R, Laterra J, Maher VM, McCormick JJ. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity. Int J Oncol. 24, 1057-67 (2004)
PubMed link      E-mail link

Reference Number: 918
Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH, Huang HY. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol. 23, 1379-92 (2010)
PubMed link      E-mail link

Poor Prognosis

Mutation of Met

In vitro studies

Reference Number: 664
Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi X, Hoang BH. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res. 68, 3350-60 (2008)
PubMed link      E-mail link

Animal models

Reference Number: 64
Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 95, 14417-22 (1998).
PubMed link      E-mail link

Reference Number: 152
Helou, K. et al. Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas. Oncogene 18, 3226-34. (1999).
PubMed link      E-mail link

Reference Number: 153
Helou, K., Walentinsson, A., Kost-Alimova, M. & Levan, G. Hgfr/Met oncogene acts as target for gene amplification in DMBA-induced rat sarcomas: free chromatin fluorescence in situ hybridization analysis of amplicon arrays in homogeneously staining regions. Genes Chromosomes Cancer 30, 416-20. (2001).
PubMed link      E-mail link

Reference Number: 154
Rong, S. et al. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 55, 1963-70 (1995).
PubMed link      E-mail link

Reference Number: 155
Webb, C. P. et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 17, 2019-25 (1998).
PubMed link      E-mail link

Reference Number: 349
Sjoling A, Walentinsson A, Nordlander C, Karlsson A, Behboudi A, Samuelson E, Levan G, Rohme D. Assessment of allele dosage at polymorphic microsatellite loci displaying allelic imbalance in tumors by means of quantitative competitive-polymerase chain reaction. Cancer Genet Cytogenet157, 97-103 (2005)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 48
Morotti, A., Mila, S., Accornero, P., Tagliabue, E. & Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21, 4885-93 (2002).
PubMed link      E-mail link

Reference Number: 918
Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH, Huang HY. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol. 23, 1379-92 (2010)
PubMed link      E-mail link

Reviews